|
Rheumatology
Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids
Yeo-Jin Lee, Soo Min Ahn, Seokchan Hong, Ji-Seon Oh, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Korean J Intern Med. 2024;39(2):338-346. Published online November 30, 2023
Background/Aims: Systemic lupus erythematosus (SLE) responder index (SRI)-4 response has been achieved with belimumab treatment in patients with moderate disease activity in cornerstone clinical trials and following studies. However, most studies involved patients treated with a mean prednisolone-eq..
|
|
|
Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park, Yeong Wook Song
Korean J Intern Med. 2022;37(5):1061-1069. Published online December 13, 2021
Background/Aims: The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Methods: Sixty Korean patients with RA who participated i..
|
|
|
Nephrology
Therapeutic effect of multiple functional minicircle vector encoding anti-CD25/IL-10/CXCR3 in allograft rejection model
Sun Woo Lim, Yoo Jin Shin, Sheng Cui, Eun Jeong Ko, Seok Ho Yoo, Byung Ha Chung, Chul Woo Yang
Korean J Intern Med. 2022;37(5):1031-1049. Published online June 21, 2022
Background/Aims: We previously proposed minicircle vector technology as the potential platform for the development and production of new biologics. In this study, we have designed a novel target molecule for the treatment of allograft rejection and evaluated its feasibility as the therapeutic agent ..
|
|
|
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
Korean J Intern Med. 2022;37(5):906-919. Published online August 10, 2022
The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the..
|
|
|
The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma
Sang-Heon Kim, Hyun Lee, So-Young Park, So Young Park, Woo-Jung Song, Joo-Hee Kim, Heung-Woo Park, You Sook Cho, Ho Joo Yoon; on behalf of the KoSAR investigators
Korean J Intern Med. 2022;37(2):249-260. Published online February 28, 2022
Severe asthma constitutes a serious health burden with significant morbidity and socioeconomic costs. The development and introduction of new biologics targeting type 2 inflammation changed the paradigm for management of severe asthma and initiated a biological era. These changes impose a challenge ..
|
|
|
Rheumatology
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
Kichul Shin, Sung Soo Kim, Sang-Heon Lee, Seung-Jae Hong, Sung Jae Choi, Jung-Yoon Choe, Seung-Geun Lee, Hoon-Suk Cha, Eun Young Lee, Sung-Hwan Park, Jin-Wuk Hur, Sung Soo Na, Chang-Hee Suh, Min Wook So, Seung Won Choi, Dong-Hyuk Sheen, Won Park, Shin-Seok Lee, Wan Hee Ryu, Jin Seok Kim, Jung Soo Song, Hye Soon Lee, Seong Ho Kim, Dae-Hyun Yoo
Korean J Intern Med. 2020;35(1):231-239. Published online January 28, 2019
Background/Aims: The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA) in daily clinical practice. Methods: This was ..
|
|
|
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Korean J Intern Med. 2020;35(1):41-59. Published online January 2, 2020
Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events ..
|
|
|
Gastroenterology
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
Korean J Intern Med. 2018;33(1):1-19. Published online December 8, 2017
Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD i..
|
|
|
Rheumatology
Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison
Miyoung Choi, Min Kyung Hyun, Seongmi Choi, Ha Jin Tchoe, Sung Yeon Lee, Kyeong Min Son, Min-Jeong Kim, Young Ok Jung, Hyun Ah Kim
Korean J Intern Med. 2017;32(3):536-547. Published online June 2, 2016
Background/Aims: Biological agents (biologics) targeting proinflammatory signaling have emerged as an important treatment option in rheumatoid arthritis (RA). Despite the clinical effectiveness of biologics for patients with RA who do not respond to ‘traditional’ disease-modifying anti-rheumatic ..
|
|
|
The specialist physician’s approach to rheumatoid arthritis in South Africa
Frederik C. J. Bester, Fredricka J. Bosch, Barend J. Jansen van Rensburg
Korean J Intern Med. 2016;31(2):219-236. Published online February 26, 2016
Rheumatoid arthritis (RA) is expected to increase in Africa and South Africa. Due to the low numbers of rheumatologists in South Africa, specialist physicians also have to care for patients with RA. Furthermore several new developments have taken place in recent years which improved the management a..
|
|
|
Current concepts in the management of rheumatoid arthritis
Yoshiya Tanaka
Korean J Intern Med. 2016;31(2):210-218. Published online February 26, 2016
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality. However, the combined use of methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), and biologic DMARD has revolutionized t..
|
|
|
S100A8/A9 as a biomarker for synovial inflammation
and joint damage in patients with rheumatoid
arthritis
Kwi Young Kang, Jung-Won Woo, Sung-Hwan Park
Korean J Intern Med. 2014;29(1):12-19. Published online January 2, 2014
S100A8 and S100A9 are major leukocyte proteins, known as damage-associated
molecular patterns, found at high concentrations in the synovial fluid of patients
with rheumatoid arthritis (RA). A heterodimeric complex of S100A8/A9 is secreted
by activated leukocytes and binds to Toll-like receptor 4,..
|
|
|
Infectious diseases
Procalcitonin as a biomarker of infectious diseases
Hyuck Lee
Korean J Intern Med. 2013;28(3):285-291. Published online May 1, 2013
Traditional biomarkers, including C-reactive protein, leukocytes, erythrocyte sedimentation rate, and clinical signs and symptoms, are not sufficiently sensitive or specific enough to guide treatment decisions in infectious febrile diseases. Procalcitonin (PCT) is synthesized by a large number of..
|
|
|
Recent Advances in Mechanisms and Treatments of Airway Remodeling in Asthma: A Message from the Bench Side to the Clinic
Jae Youn Cho
Korean J Intern Med. 2011;26(4):367-383. Published online November 28, 2011
Airway remodeling in asthma is a result of persistent inflammation and epithelial damage in response to repetitive injury. Recent studies have identified several important mediators associated with airway remodeling in asthma, including transforming growth factor-β, interleukin (IL)-5, basic fib..
|
|
|
Diagnostic Value of a Chimeric TSH Receptor (Mc4)-Based Bioassay for Graves' Disease
Ji In Lee, Hye Won Jang, Soo Kyoung Kim, Joon Young Choi, Ji Young Kim, Kyu Yeon Hur, Jae Hyeon Kim, Yong-Ki Min, Jae Hoon Chung, Sun Wook Kim
Korean J Intern Med. 2011;26(2):179-186. Published online June 1, 2011
Background/AimsGraves' disease (GD) is caused by thyroid-stimulating hormone receptor (TSHR) and thyroid-stimulating immunoglobulin (TSI). We used a recently introduced, technically enhanced TSI bioassay to assess its diagnostic value and determine the cut-off in patients in h..
|
|
|
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage, Harsh Agrawal, Daniel E. Furst
Korean J Intern Med. 2010;25(1):1-17. Published online February 26, 2010
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and 2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and reviews were examined. There were thirteen articles on abatacept, four on goli..
|
|
|
Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency
Hye Won Kim, Yeon Ju Lee, You-Jung Ha, Eun Bong Lee, Yun Jong Lee, Eun Ha Kang
Received June 27, 2023 Accepted October 30, 2023 Published online February 29, 2024
Background/Aims: This cross-sectional study aimed to investigate biologics treatment disparities in rheumatoid arthritis (RA) patients based on socioeconomic status (SES).
Methods: Data from the KOrean Observational Study Network for Arthritis (KORONA) database were analyzed to assess various facto..
|
|
|
